Gregory Berk

CIK 1306870 · Pres. of R&D, CMO · last filed 2022-07-19

Gregory Berk is a Pres. of R&D, CMO who has filed 10 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for GTBP, was dated Jul 19, 2022. Current disclosed insider exposure totals $2.9K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$2.9K

Companies

5

Total Filings

10

Lifetime Open-Market Net

$0

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
GTBP	Pres. of R&D, CMO	9,269	$0.32	$2.9K	$0	2	2022-07-19
VSTM	Chief Medical Officer	—	$6.23	—	$0	3	2017-01-11
DNIB UNWIND, INC. (BIND) Delisted	Chief Medical Officer	—	—	—	$0	1	2014-01-15
Astex Pharmaceuticals, Inc (SUPG) Delisted	Chief Medical Officer	—	—	—	$0	3	2009-03-16
Talon Therapeutics, Inc. (HNAB) Delisted	Senior VP & Chief Medical Offr	5,500	—	—	$0	1	2007-01-24

Recent Filings

10 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2022-07-19	GTBP	Grant (A)	—	$0	EDGAR
2022-02-14	GTBP	Grant (A)	+278,058	$0	EDGAR
2017-01-11	VSTM	Grant (A)	—	$0	EDGAR
2016-11-01	VSTM	Grant (A)	—	$0	EDGAR
2016-04-19	VSTM	Grant (A)	—	$0	EDGAR
2014-01-15	DNIB UNWIND, INC. (BIND) Delisted	Mixed	—	$0	EDGAR
2009-03-16	Astex Pharmaceuticals, Inc (SUPG) Delisted	Grant (A)	—	$0	EDGAR
2008-03-17	Astex Pharmaceuticals, Inc (SUPG) Delisted	Grant (A)	—	$0	EDGAR
2007-05-30	Astex Pharmaceuticals, Inc (SUPG) Delisted	Grant (A)	—	$0	EDGAR
2007-01-24	Talon Therapeutics, Inc. (HNAB) Delisted	Mixed	—	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.